Literature DB >> 12233978

Experimental and clinical psychopharmacology: National Institute on Drug Abuse's clinical research agenda.

Alan I Leshner1.   

Abstract

Studies of drugs and behavior are a core component of virtually every portfolio within the broad purview of the National Institute on Drug Abuse (NIDA). Moreover, psychopharmacological research is an important vehicle for advancing understanding of how drugs of abuse produce their effects, particularly including addiction. However, as with all major public health issues, simply understanding the issue is not enough. NIDA's psychopharmacology projects, therefore, span basic, clinical, and applied (e.g., medication development) research activities. These include the establishment of a nationwide clinical trials network designed to provide an infrastructure to test both behavioral and psychopharmacological treatments in a real-life practice setting with diverse patients.

Entities:  

Mesh:

Year:  2002        PMID: 12233978     DOI: 10.1037//1064-1297.10.3.159

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  2 in total

1.  Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: a summary of findings.

Authors:  Shelly F Greenfield; Carmen Rosa; Susan I Putnins; Carla A Green; Audrey J Brooks; Donald A Calsyn; Lisa R Cohen; Sarah Erickson; Susan M Gordon; Louise Haynes; Therese Killeen; Gloria Miele; Susan Tross; Theresa Winhusen
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

2.  Quality assurance of research protocols conducted in the community: the National Institute on Drug Abuse Clinical Trials Network experience.

Authors:  Carmen Rosa; Aimee Campbell; Cynthia Kleppinger; Royce Sampson; Clare Tyson; Stephanie Mamay-Gentilin
Journal:  Clin Trials       Date:  2009-04       Impact factor: 2.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.